Immunotherapy for Early-Stage Resectable NSCLC: Optimizing Multidisciplinary Management Today

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelinesПодробнее

8 in 8 Series: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLCПодробнее

Has Immunotherapy Brought Us to an Inflection Point in the Management of Stage I-III NSCLC?Подробнее

Dr Akhil Kapoor | Systemic Therapy Sequencing in Early Stage Resectable NSCLCПодробнее

Early-Stage Resectable NSCLC: A Shifting Landscape With Targeted Therapies and ImmunotherapyПодробнее

Multidisciplinary Management of Patients With Stage III NSCLCПодробнее

Optimizing Neoadjuvant Immunotherapy in NSCLC by Dr. Kaushik | Oncology Perspective 2024Подробнее

The Role of Immunotherapy in Late Stage NSCLC WebinarПодробнее

Surgical perspective on neoadjuvant IO for resectable stage III NSCLCПодробнее

Locally Advanced NSCLC: How to Optimize Your Tumor BoardПодробнее

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLCПодробнее

The role of surgery in early-stage NSCLC management | Jessica DoningtonПодробнее

8 in 8: Update on Immunotherapy for Resectable Lung CancerПодробнее

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLCПодробнее

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Multidisciplinary consensus for the definition of resectable NSCLCПодробнее

Immunotherapy as combination and neoadjuvant therapies in NSCLCПодробнее

TOPS Mount Sinai: Treating Actionable Mutations in Stage IV NSCLCПодробнее

Immunotherapy in Early Stage NSCLCПодробнее